Uses of anti-CX3CR1 antibody, anti-fractalkine antibody and fractalkine
US7390490B1 · kind B1 · utility
3Cited by
1References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 13, 2005 |
| Grant date | Jun 24, 2008 |
| Priority date | — |
| Expiry date | Oct 4, 2025 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S424/81
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
There are provided uses of an antibody directed to CX3CR1 and fractalkine. Killer lymphocytes can be readily identified, eliminated and separated by using an anti-CX3CR1 antibody. Further, there can be provided an antibody drug for suppressing chemotaxis and cytotoxic activity of killer lymphocytes by suppressing an interaction between CX3CR1 and fractalkine.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.